Type 2 Diabetes Clinical Trial
Official title:
The Impact of Food Order/Nutrient Sequence on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose Monitoring
| NCT number | NCT04738799 |
| Other study ID # | 20-03021613 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | April 29, 2021 |
| Est. completion date | July 3, 2023 |
| Verified date | October 2023 |
| Source | Weill Medical College of Cornell University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to explain the effect of food order/nutrient sequencing on glycemic excursions over a 2 week period, utilizing a device known as a continuous glucose monitor (CGM), for people who have been diagnosed with Type 2 Diabetes Mellitus and treated with metformin. This research study is being done because recent studies demonstrate that besides carbohydrate amount and type, the sequential order of macronutrient consumption during a meal has a significant impact on post-meal glucose levels.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | July 3, 2023 |
| Est. primary completion date | July 3, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years and older |
| Eligibility | Inclusion Criteria: - Metformin-treated type 2 diabetes of less than 10 years duration - Must be on a stable dose of metformin for at least 1 month - HbA1c =8.5 percent Exclusion Criteria: - Relevant food allergies - Oral steroid therapy within 90 days of enrollment - Anti-diabetic medications other than metformin - History of bariatric surgery - Pregnant women - Any participant deemed unsuitable in the investigator's opinion |
| Country | Name | City | State |
|---|---|---|---|
| United States | Weill Cornell Medicine | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Weill Medical College of Cornell University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in incremental glucose peak, under controlled conditions | Day 6, Day 12 | ||
| Primary | Change in mean amplitude of glycemic excursion, under controlled conditions | Day 6, Day 12 | ||
| Primary | Change in time in range, under controlled conditions | Time during which participant maintained a blood glucose level between 70-180mg/dL over 8 hour observation period | Day 6, Day 12 | |
| Secondary | Change in incremental glucose peak, under free-living conditions | Day 1 through 5, Day 7 through 11 | ||
| Secondary | Change in mean amplitude of glycemic excursion, under free-living conditions | Day 1 through 5, Day 7 through 11 | ||
| Secondary | Change in time in range, under free-living conditions | Time during which participant maintained a blood glucose level between 70-180mg/dL | Day 1 through 5, Day 7 through 11 | |
| Secondary | Change in postprandial insulin concentration | Postprandial concentrations of insulin measured at 30-minute intervals for 180 minutes following standardized meal administration. | Day 6, Day 12 | |
| Secondary | Change in postprandial c-peptide concentration | Postprandial concentrations of c-peptide measured at 30-minute intervals for 180 minutes following standardized meal administration. | Day 6, Day 12 | |
| Secondary | Change in postprandial ghrelin concentration | Postprandial concentrations of ghrelin measured at 30-minute intervals for 180 minutes following standardized meal administration. | Day 6, Day 12 | |
| Secondary | Change in postprandial PYY concentration | Postprandial concentrations of PYY measured at 30-minute intervals for 180 minutes following standardized meal administration. | Day 6, Day 12 | |
| Secondary | Change in postprandial GLP-1 concentration | Postprandial concentrations GLP-1 measured at 30-minute intervals for 180 minutes following standardized meal administration. | Day 6, Day 12 | |
| Secondary | Change in postprandial CCK concentration | Postprandial concentrations of CCK measured at 30-minute intervals for 180 minutes following standardized meal administration. | Day 6, Day 12 | |
| Secondary | Change in satiety, as measured by Visual Analog Scale (VAS) | Scores are measured on a 100mm VAS. The VAS ranges from 0 to 100, with 0 indicating lower satiety and higher scores indicating greater satiety. | Day 6, Day 12 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |